CTIS2024-514060-10-00招募中1 期
Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative or Luminal Breast Cancer. – The PRIMED Study – - MEDOPP445
Medica Scientia Innovation Research S.L.0 个研究点目标入组 50 人开始时间: 2024年6月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed Informed Consent Form (ICF) prior to participation in any study-related activities., For HR positive luminal breast cancer patients only: b.) Refractory to at least 1 prior anticancer hormonal treatment and at least 1 CDKi4/6 in the metastatic setting., Measurable or non-measurable, but evaluable disease, as per RECIST v.1.1. Patients with bone-only metastases are also eligible., Brain MRI must be done for patients with suspicion of brain metastases and patient must have stable central nervous system (CNS) disease for at least 4 weeks after local therapy, without neurological symptoms, and off anticonvulsants and steroids for at least 2 weeks before first dose of study treatment., Adequate hematologic counts without transfusion or growth factor support within 2 weeks before of study drug initiation (hemoglobin = 9 g/dL, ANC = 1500/mm3 , and platelets = 100,000/µL)., Adequate renal and hepatic function (creatinine clearance of = 60 ml/min, may be calculated using Cockcroft-Gault equation; bilirubin = 1.5 x ULN, AST and ALT = 3.0 x ULN or 5 x ULN if known liver metastases), Resolution of all acute AEs of prior anti-cancer therapy to grade 1 as determined by the NCI-CTCAE v.5.0 (except for alopecia or other toxicities not considered a safety risk for the patient at investigator discretion)., Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use institution specified method(s) of contraception., Patients must have completed all prior cancer treatments at least 2 weeks* prior to randomization including chemotherapy (includes also endocrine treatment), radiotherapy, and major surgery., *Prior antibody treatment for cancer must have been completed at least 3 weeks prior to randomization., Patients aged =18 years at the time of signing ICF., Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1., Life expectancy of = 12 weeks, Unresectable locally advanced or metastatic disease documented by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent., All patients must have been previously treated with taxanes regardless of disease stage (adjuvant, neoadjuvant, or advanced), unless contraindicated for a given patient., Refractory to at least one, and no more than two, prior standard of care chemotherapy regimens for unresectable locally advanced or MBC. Earlier adjuvant or neoadjuvant therapy for more limited disease will be considered as one of the required prior regimens if the development of unresectable locally advanced or metastatic disease occurred within a 12-month period after completion of chemotherapy or immunotherapy (e.g., adjuvant pembrolizumab)., For TNBC patient only: Histologically confirmed TNBC per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria based on local testing on the most recent analyzed biopsy. Triple-negative is defined as <1% expression for estrogen receptor (ER) and progesterone receptor (PgR) and negative for human epidermal growth factor receptor 2 (HER2) (0–1+ by IHC or 2+ and negative by in situ hybridization [ISH) test]., For HR positive luminal breast cancer patients only: a.) Confirmed diagnosis of estrogen receptor (ER)[+] and/or progesterone receptor (PR)[+] (with =1% positive stained cells according to National Comprehensive Cancer Network [NCCN] and American Society of Clinical Oncology [ASCO] guidelines) and
排除标准
- •Prior treatment with topoisomerase 1 inhibitors as a free form or as other formulations., Active or prior documented inflammatory bowel disease (i.e. Crohn's disease, ulcerative colitis, or a preexisting chronic condition resulting in baseline grade =1 diarrhea)., Infection requiring antibiotic use within 1 week of randomization., Other concurrent medical or psychiatric conditions that, in the Investigator’s opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations., Women who are pregnant or lactating., Concomitant participation in other interventional clinical trial., Patients with carcinomatous meningitis or leptomeningeal disease., Known hypersensitivity reaction to any investigational or therapeutic compound or their incorporated substances., Patients with Gilbert's disease., Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive., Participants with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while participants with other prior malignancies must have had at least a 3-year disease-free interval., Known history of unstable angina, myocardial infarction, or cardiac heart failure present within 6 months of study initiation or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy or history of QT interval prolongation., Known history of clinically significant active Chronic obstructive pulmonary disease (COPD), or other moderate-to-severe chronic respiratory illness present within 6 months of study initiation, Known history of clinically significant bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months of study initiation.
研究者
相似试验
招募中
不适用
Phase 2 open-label, single-arm, multi-center clinical trial to evaluate the efficacy and safety of Camostat mesylate in patients with Protein-losing enteropathy after Fontan operatioKCT0007666Seoul National University Hospital30
已完成
2 期
Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulatio•Transfusion-dependent Thalassemia•Non-transfusion-dependent ThalassemiaD56.9ThalassemiaLBCTR2019020189ovartis Pharma Services Inc.5
进行中（未招募）
不适用
Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIOEUCTR2010-021062-29-ITOVARTIS FARMA45
进行中（未招募）
不适用
Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIOtransfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overloadMedDRA version: 13.1Level: LLTClassification code 10065974Term: Chronic iron overloadSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-021062-29-GRovartis Pharma Services AG45
尚未招募
2 期
Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-20202024-519106-12-00G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica33